Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
All News
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised.
A current review of the epidemiology of IgG4-related disease (IgG4-RD) in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder.
This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.
Aging Mechanisms Tied to Giant Cell Arteritis
Senescence pathways are involved in giant cell arteritis (GCA), an analysis of patient tissue samples suggested, which may account for the efficacy of one agent now used for the disease and another in commercial development.
